Change the World 2023
Early detection and diagnosis can reduce cancer mortality rates by 26%. Health care startup Grail aims to make that reduction more common with Galleri, a multicancer early detection (MCED) blood test that can detect a shared cancer signal across more than 50 types of cancers. Galleri complements physician-recommended single-cancer screenings and can help detect cancer in its early stages, when treatment is more likely to be successful.
Since releasing Galleri in 2021, Grail has had over 100,000 physician orders for the test. The initiative has yet to turn a profit, but its revenue doubled in the first quarter of 2023 year over year, largely driven by test volume growth. MCED tests are not yet FDA-approved. However, Galleri was granted FDA Breakthrough Device designation in 2019, which expedites the approval process so that more patients can access the technology sooner.
Since releasing Galleri in 2021, Grail has had over 100,000 physician orders for the test. The initiative has yet to turn a profit, but its revenue doubled in the first quarter of 2023 year over year, largely driven by test volume growth. MCED tests are not yet FDA-approved. However, Galleri was granted FDA Breakthrough Device designation in 2019, which expedites the approval process so that more patients can access the technology sooner.
Courtesy of GRAIL